Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Hangzhou Zhongmei Huadong Pharmaceutical is the lead sponsor of 35 current clinical trials in our China register. 24 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are HDM1002, HDM1005 and HDM1005 1. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

Recruiting2469%
Not yet open1029%
Active, closed13%

Trials by phase

Phase 11851%
Phase 3926%
Phase 1/239%
Phase 239%
Phase 426%

Clinical trials sponsored by Hangzhou Zhongmei Huadong Pharmaceutical

35 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control NCT07244003 · T2DM (Type 2 Diabetes Mellitus) Drugs: Ganagliflozin, Liraglutide, Metformin	Phase 4	Recruiting	2025-03	China
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients NCT07036172 · ClinicalTrials.gov ↗ · Obesity Control Drug: Wegovy	Phase 3	Recruiting	2025-01	China
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma NCT07124936 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL) Drugs: Cyclophosphamide, Doxorubicin, Gemcitabine	Phase 1/2	Recruiting	2025-07	China
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes NCT07279194 · ClinicalTrials.gov ↗ · Obesity & Overweight Drugs: HDM1005 1, HDM1005 2	Phase 3	Recruiting	2025-10	China
A Phase 1 Study of HDM2017 in Advanced Solid Tumors NCT07274085 · ClinicalTrials.gov ↗ · Solid Tumors Drug: HDM2017	Phase 1	Recruiting	2025-11	China
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor NCT06615193 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy Drug: HDM2005	Phase 1	Recruiting	2024-08	China
A Study of HDM2005 in Patients With Advanced Solid Tumor NCT07004296 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: HDM2005	Phase 1	Recruiting	2025-05	China
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes NCT07521631 · ClinicalTrials.gov ↗ · Obesity Drugs: HDM1005, Tirzepatide	Phase 2	Recruiting	2026-03	China
A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects NCT07594847 · ClinicalTrials.gov ↗ · Healthy Adult Subject Drugs: HDM1002, Moxifloxacin	Phase 1	Recruiting	2026-03	China
A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement NCT06985615 · ClinicalTrials.gov ↗ · Hepatic Impairment, Healthy Volunteers	Phase 1	Recruiting	2025-03	China
A Study of HDM2012 in Patients With Advanced Solid Tumor NCT07100249 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2025-08	China
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone NCT07394114 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drugs: HDM1005 1, HDM1005 2	Phase 3	Recruiting	2026-02	China
A Study of HDM2006 in Patients With Advanced Solid Tumor NCT07377591 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2024-12	China
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma NCT07529782 · ClinicalTrials.gov ↗ · Multiple Myeloma and Other Plasma Cell Neoplasms Drug: HDP-101	Phase 1	Recruiting	2026-03	China
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer NCT07805551 · ClinicalTrials.gov ↗ · CRC, Colorectal Cancer Drugs: Bevacizumab, Capecitabine, Fluorouracil	Phase 1/2	Recruiting	2026-08	China
A Study of HDM2020 in Patients With Advanced Sq-NSCLC NCT07638891 · ClinicalTrials.gov ↗ · Squamous Non-small Cell Lung Cancer(NSCLC)	Phase 1	Recruiting	2026-04	China
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus NCT07193459 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drug: HDM1002	Phase 3	Recruiting	2025-08	China
A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects NCT06576401 · ClinicalTrials.gov ↗ · Healthy Adult Subject	Phase 1	Recruiting	2024-08	China
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus NCT06886126 · ClinicalTrials.gov ↗ · Obesity	Phase 2	Recruiting	2025-02	China
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin NCT07331389 · ClinicalTrials.gov ↗ · Overweight Subject, Healthy Subjects	Phase 1	Recruiting	2025-09	China
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin NCT07109700 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drugs: Dulaglutide, HDM1005 1, HDM1005 2	Phase 2	Recruiting	2025-04	China
A Study of HDM2024 in Participants With Advanced Solid Tumors NCT07539285 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2026-04	China
A Study of HDM2020 in Patients With Advanced Solid Tumors NCT07098052 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	2025-08	China
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus NCT07082114 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drugs: Dapagliflozin, HDM1002	Phase 3	Recruiting	2025-07	China
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis NCT07683806 · ClinicalTrials.gov ↗ · Seborrheic Dermatitis	Phase 3	Not yet open	2026-08	China
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease NCT07116928 · ClinicalTrials.gov ↗ · T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease Drug: Ganagliflozin	Phase 4	Not yet open	2025-11	China
A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects NCT06608329 · ClinicalTrials.gov ↗ · Healthy Adult Subject Drug: HDM1002	Phase 1	Not yet open	2024-10	China
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy NCT07794397 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea (OSA) and Obesity Drug: HDM1005	Phase 3	Not yet open	2026-09	China
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor NCT07417306 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drugs: HDM1005 1, HDM1005 2, Mazdutide	Phase 3	Not yet open	2026-03	China
A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants NCT07559240 · ClinicalTrials.gov ↗ · Overweight, Obese	Phase 1	Not yet open	2026-05	China
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin NCT07502001 · ClinicalTrials.gov ↗ · Overweight, Obesity Drugs: Acetaminophen, Atorvastatin, Digoxin	Phase 1	Not yet open	2026-04	China
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy NCT07787260 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea (OSA) and Obesity Drug: HDM1005	Phase 3	Not yet open	2026-08	China
A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer NCT07621159 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 1/2	Not yet open	2026-07	China
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. NCT06601517 · ClinicalTrials.gov ↗ · Healthy Adult Subject, Overweight Subject Drugs: Atorvastatin, Digoxin, HDM1002	Phase 1	Not yet open	2024-10	China
A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites NCT07828197 · ClinicalTrials.gov ↗ · Overweight and/or Obesity, Healthy Participants Drug: HDM1005	Phase 1	Active, closed	2026-09	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Hangzhou Zhongmei Huadong Pharmaceutical trials

33 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Hangzhou Zhongmei Huadong Pharmaceutical trials

27 conditions

Advanced Solid Tumors5 Type 2 Diabetes5Healthy Adult Subject4Obesity3T2DM (Type 2 Diabetes Mellitus)2Obstructive Sleep Apnea (OSA) and Obesity2Overweight2Overweight Subject2Obesity Control1Diffuse Large B Cell Lymphoma (DLBCL)1 Obesity & Overweight1Seborrheic Dermatitis1Solid Tumors1Refractory Lymphoma1Relapsed Hematologic Malignancy1CKD - Chronic Kidney Disease1Hepatic Impairment1 Healthy Volunteers1Obese1Multiple Myeloma and Other Plasma Cell Neoplasms1CRC, Colorectal Cancer1Overweight and/or Obesity1Healthy Participants1Squamous Non-small Cell Lung Cancer(NSCLC)1

By trial register

Register	Trials	Recruiting
Clinical trials in China	35	24

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Advanced Solid Tumors

Sponsor	Trials
Sichuan Kelun-Biotech Biopharmaceutical	9
Jiangsu HengRui Medicine	7
Suzhou Suncadia Biopharmaceuticals	7
Shanghai Hengrui Pharmaceutical	6
Bristol-Myers Squibb	5
MediLink Therapeutics (Suzhou)	5
Hansoh BioMedical R&D Company	4
Bayer	3
Vividion Therapeutics	3
Multitude Therapeutics	3

Sponsors with the most current trials registered for this condition.

Questions about Hangzhou Zhongmei Huadong Pharmaceutical trials

How many clinical trials does Hangzhou Zhongmei Huadong Pharmaceutical sponsor?

Hangzhou Zhongmei Huadong Pharmaceutical is the lead sponsor of 35 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hangzhou Zhongmei Huadong Pharmaceutical trials recruiting?

Yes. 24 of its 35 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hangzhou Zhongmei Huadong Pharmaceutical testing?

Its current trials name 33 drugs and biologicals as interventions. The most frequent are HDM1002 (5), HDM1005 (5), HDM1005 1 (4), HDM1005 2 (4) and HDM2005 (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Hangzhou Zhongmei Huadong Pharmaceutical clinical trials